Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 12/20 | 0.44 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | STK10 | O94804 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756198 | 0.83 | KDR (0.61) | ABCB1F10KDRALDH1A1BDKRB1 | |
| SCHEMBL6780369 | 0.81 | ABCB1 (0.54) | ABCB1F10KDRALDH1A1BDKRB1 | |
| SCHEMBL5760386 | 0.81 | F10 (0.72) | ABCB1F10KDRALDH1A1BDKRB1 | |
| Hydrochloric Acid SCHEMBL6774852 | 0.80 | ABCB1 (0.53) | ABCB1F10KDRALDH1A1BDKRB1 | |
| SCHEMBL445730 | 0.80 | KDR (0.67) | ABCB1KDRCITMAP3K7RIPK2 | |
| SCHEMBL6168414 | 0.78 | RXFP2 (0.69) | F10RXFP2 | |
| Ammonia Solution, Strong SCHEMBL5757646 | 0.77 | F10 (0.58) | ABCB1F10BDKRB1 | |
| Hydrochloric Acid SCHEMBL6890222 | 0.77 | F10 (0.54) | ABCB1F10KDRALDH1A1BDKRB1 | |
| Hydrochloric Acid SCHEMBL6773419 | 0.75 | F10 (0.55) | ABCB1F10KDRALDH1A1BDKRB1 | |
| Hydrochloric Acid SCHEMBL6774426 | 0.75 | F10 (0.53) | ABCB1F10KDRALDH1A1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6780878-B2 | ANTICOAGULANTS; CARDIOVASACULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6716855-B2 | INHIBITOR OF FACTOR XA; N1-(BENZOYL)-N2-(1-(4-PYRIDYL)PIPERIDIN-4-YL-METHYL)-1,2-BENZENDIAMINE HIGH BIOAVAILABILITY | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6710057-B2 | INHIBITORS OF FACTOR XA, AS ANTICOAGULANTS FOR PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20030212069-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
| US-6610704-B1 | Inhibit factor Xa | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1140881-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039111-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | ABCB1 1732/4885F10 13/4885KDR 1677/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | ABCB1 1732/4885F10 13/4885KDR 1677/4885 |
| US-20030212069-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | ABCB1 1732/4885F10 13/4885KDR 1677/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | ABCB1 1732/4885F10 13/4885KDR 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.